TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04856202

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance Care Planning interview
Description: The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
Study: NCT06538649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin provided at 10 mg start; 5mg for Asians. Dose will be increased to 20 mg for those tolerating and without contraindication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet(s)
Study: NCT04654468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.
Study: NCT05659966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Participants will receive a behavioral intervention on a plant-based diet in partnership with a local restaurant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voucher only
Description: Participants will receive vouchers to a local restaurant. Participants will not attend nutrition classes but will receive a class at the end of the 12-week study.
Study: NCT06451250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult Day Service use for family member with dementia
Description: Self-collection of salivary biomarkers 4 times daily for 5 days, two of those days the family member with dementia has to use adult day services
Study: NCT05570253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDX-7320
Description: SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDX-7320
Description: SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05113095

Intervention type: BIOLOGICAL
Intervention: Darvadstrocel
Description: Darvadstrocel injection
Study: NCT05354947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Delivery
Description: A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Delivery
Description: A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
Study: NCT04743505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: -Provided by Apollomics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: -Provided by Apollomics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: -Provided by Apollomics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: -Given standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: -Given standard of care
Study: NCT04872218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 24 week treatment of IV abatacept following recommended dosages from the monograph

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 week treatment of IV placebo following recommended dosages from the abatacept monograph

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peanut oral immunotherapy
Description: Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
Study: NCT05028738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.
Study: NCT06193486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSGV1-PSCA-8T28Z
Description: Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSGV1-PSCA-8T28Z
Description: Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antimetabolite given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antimetabolite given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
Study: NCT05981391

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinician Administered PTSD Scale for the DSM-5 (CAPS-5)
Description: The CAPS-5 is a semi-structured interview, conducted by an independent evaluator, that measures DSM-5 symptoms of PTSD. Presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for 1 month or more are required to reach the diagnostic threshold.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinician Administered PTSD Scale for the DSM-5 (CAPS-5)
Description: The CAPS-5 is a semi-structured interview, conducted by an independent evaluator, that measures DSM-5 symptoms of PTSD. Presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for 1 month or more are required to reach the diagnostic threshold.
Study: NCT06336746

Intervention type: DEVICE
Intervention: Esophageal Doppler
Description: Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.

Intervention type: DEVICE
Intervention: Esophageal Doppler
Description: Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.

Intervention type: DEVICE
Intervention: Esophageal Doppler
Description: Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
Study: NCT06184477

Intervention type: OTHER
Intervention: PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION
Description: we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon

Intervention type: OTHER
Intervention: PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION
Description: we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon
Study: NCT06224075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-specific training
Description: Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
Study: NCT05210842

Intervention type: OTHER
Intervention: Endoscopy
Description: The procedures are performed using a flexible therapeutic linear array echoendoscope.
Study: NCT05981391

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tinnitus Assessment
Description: Tinnitus acoustic assessment (for tinnitus participants only): Tinnitus ear (left, right, bilateral), pitch matched frequency (Hz) and loudness matched intensity (dB) will be conducted. When available, the tinnitus acoustic assessment only will be repeated at the RII, on the same day and prior to the fMRI scan, to demonstrate reproducibility of results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tinnitus Assessment
Description: Tinnitus acoustic assessment (for tinnitus participants only): Tinnitus ear (left, right, bilateral), pitch matched frequency (Hz) and loudness matched intensity (dB) will be conducted. When available, the tinnitus acoustic assessment only will be repeated at the RII, on the same day and prior to the fMRI scan, to demonstrate reproducibility of results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoscopy
Description: Otoscopy is a clinical procedure used to examine structures of the ear, particularly the external auditory canal, tympanic membrane, and middle ear

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoscopy
Description: Otoscopy is a clinical procedure used to examine structures of the ear, particularly the external auditory canal, tympanic membrane, and middle ear
Study: NCT05727059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Elevate™ System
Description: The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
Study: NCT06234397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH3120
Description: BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH3120
Description: BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
Study: NCT05932329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice provided
Study: NCT06228703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device with flow setting at 40 L/min or higher
Description: Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device with flow setting at 40 L/min or higher
Description: Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device with flow setting at 40 L/min or higher
Description: Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
Study: NCT06003400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study treatment administration (TriO FITT)
Description: Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology Blood Tests
Description: complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry Blood Test
Description: urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wound Digital Photography
Description: 3 photographs of the wound taken before wash, after wash and after treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine pregnancy test
Description: for women with childbearing potential

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Description: Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-36
Description: SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wounds evaluation
Description: including size measurements and visual description.
Study: NCT06213545

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In-clinic interpretation
Description: Reading patch test result at clinic

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In-clinic interpretation
Description: Reading patch test result at clinic

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photo interpretation
Description: Reading patch test result by sending photo to clinic

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photo interpretation
Description: Reading patch test result by sending photo to clinic
Study: NCT04852783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System
Description: Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
Study: NCT06485687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFU Neuromodulation
Description: Subjects will undergo a single LIFU of the target brain region
Study: NCT04767282

Intervention type: OTHER
Group type: OTHER
Intervention: Fruit and Vegetable Prescription
Description: $15 voucher for fruit and vegetables
Study: NCT05526989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: 300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
Study: NCT05788796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band-aid application
Description: Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid.
Study: NCT05295680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hymecromone
Description: Hymecromone 400 mg 3 times daily by mouth.
Study: NCT05617209

Intervention type: OTHER
Intervention: thrombin generation measurement
Description: Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
Study: NCT05379725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Dietary Pattern
Description: The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fermented Food Dietary Pattern
Description: Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.